Please login to the form below

Not currently logged in
Email:
Password:

Pfizer launches generics portfolio in the UK

Pharmacy customers benefit as Pfizer provides a further six generic medicines

Pfizer has launched six generic medicines for pharmacy and dispensing customers in the UK. The products are part of the company's Established Products Business Unit portfolio of over 80 off-patent medicines and were added to its armoury following agreements with generics manufacturers Aurobindo Pharma and Claris Lifesciences in 2009.

The six medicines include; metformin, finasteride, ondansteron, paroxetine, mirtazapine and mirtazapine OD for disorders including, type 2 diabetes, benign prostatic hyperplasia, post-operative nausea and vomiting, and depression.

"Our generic medicines will continue to deliver commercial value to pharmacists through Pfizer's A Healthy Partnership pharmacy programme by providing our customers with a wider product offering," said Steve Poulton, commercial director and head of the Established Products Business Unit.

In 2008, Pfizer launched A Healthy Partnership, following research into the pharmacy community's understanding of the pharmacy contractual framework, to support community pharmacists in their important role of delivering healthcare and new services to patients.

Results from the review showed that there was variable understanding among pharmacists of exactly what the new contractual framework entailed. The research also confirmed that community pharmacy was in professional transition, with the pharmacist's role evolving from traditional dispensing towards greater involvement in delivering frontline care.

A Healthy Partnership includes a range of support packages to help pharmacists achieve specific objectives within the pharmacy contractual framework and works with community pharmacy in three important areas:

  • Supporting professional development: giving support to pharmacists as frontline healthcare professionals 
  • Enhancing the patient experience: improving outcomes through patient-focused programmes 
  • Delivering commercial value: recognising the commercial aspect of pharmacy business

3rd February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics